Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Stomach Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Composite Lymphoma 1Colorectal Neoplasms 1

Interventions

Rituximab 23Cyclophosphamide 15ibrutinib 14acalabrutinib 13CT-P10 10venetoclax 8Lenalidomide 8Bendamustine Hydrochloride 8fludarabine 7Cytarabine 6fludarabine phosphate 5zanubrutinib 4obinutuzumab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4pirtobrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Etoposide 3palbociclib 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2brexucabtagene autoleucel 2auricularum 2Vincristine 2Stem Cell Transplantation 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Mantle-Cell × ALX148 × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡